

Happy  
New year

We hope you had a wonderful holiday season! Your participation in the AHEAD Study is extremely important to the advancement of Alzheimer's disease research. Thank you for your continued support. We look forward to continuing our work together to find a treatment that works for everyone.

## News and updates from the AHEAD Study Team

We are excited to share that the AHEAD Study, testing the investigational treatment lecanemab in study participants with amyloid plaques before Alzheimer's disease symptoms start, has added an 'open-label' extension phase. In 2023, lecanemab was granted full FDA approval by the FDA as a treatment for people with Mild Cognitive Impairment (MCI) or mild dementia due to Alzheimer's disease. As an AHEAD Study participant, regardless of which treatment arm you were assigned to (lecanemab or placebo), you can receive the treatment if you complete the study's full duration, or if you experience progression to MCI or dementia during the study and are approved for the treatment by your site's principal investigator.



Dr. Reisa  
Sperling

**"The open-label extension is an important opportunity for our AHEAD Study clinical trial volunteers to receive lecanemab at no cost. Your participation is helping us make critical progress in understanding Alzheimer's disease and learning about whether earlier intervention with lecanemab may help us one day prevent dementia. Thank you for your dedication to the AHEAD Study. We cannot do it without you!"**

## Did You See This?

Dear Abby responded to Dr. Sperling's AHEAD Study letter: "Clinical trial volunteers are key to better treatments, prevention strategies and a future cure for Alzheimer's disease". Read the full letter and Dear Abby's response [here](#).



# Healthy Habits

## Challenge Yourself to Try Something New Everyday



Explore a local museum



Read books in different genres



Try crafting or an artistic hobby



Discover new recipes to cook



Learn to play an instrument

Mr. Bill Kerr, involved in the AHEAD Study since 2020, says he participates because he has been personally affected by Alzheimer's disease and understands the difficulties for families and caregivers.


"Having experienced it myself from my mother and her sister, I know what a difficult thing it can be, obviously, for them and for the people that are caring for them. It affects millions." - **Bill Kerr**

Read more about Bill's story by Stephen Langel of Ideastream Public Media [here](#).

## AHEAD Study Participant Spotlights

Kelley Ewing is a dedicated participant enrolled in the AHEAD Study and has personal inspiration to be involved in Alzheimer's research because his wife, Jolene Ewing, has been diagnosed with Alzheimer's disease.

Read more about Kelley and Jolene's story by Stephanie Stahl of CBS News Philadelphia [here](#).



# THANK YOU!



Interested in becoming a participant spotlight for the AHEAD Study? Reach out to your site about potential local media opportunities!

